Trackers› Clinical trials› Massachusetts

Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC

9144

Studies in scope

industry-sponsored, all four open statuses

4957

Recruiting now

open to new participants

2196

Lead sponsors

across recruiting studies

Top states

California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246

Trials with a site in Massachusetts

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Active, closed

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

NCT05682443Metastatic Castration-resistant Prostate Cancer

DrugsLutetium Lu-177 vipivotide tetraxetan·Gotistobart

OncoC4, Inc.

Phase 1/2

148

California, Colorado, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nebraska

2023-12-11

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

110

Arizona, Arkansas, California, Colorado, Florida, Indiana, Massachusetts, Minnesota

2023-12-11

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

California, Colorado, Florida, Idaho, Illinois, Massachusetts, New York, North Carolina

2023-12-11

Active, closed

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

DrugBel-sar

Aura Biosciences

Phase 3

108

California, Georgia, Illinois, Massachusetts, Michigan, Minnesota, New York, Ohio

2023-12-06

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945Multiple Myeloma

DrugsElranatamab·Pomalidomide·Dexamethasone

AstraZeneca

Phase 1/2

226

California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia

2023-12-05

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT06034002Myeloproliferative Neoplasms

DrugsINCA033989·Ruxolitinib

Incyte Corporation

Phase 1

290

California, Florida, Kansas, Maryland, Massachusetts, Missouri, New York, North Carolina

2023-12-04

Active, closed

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095Eosinophilic Oesophagitis

DrugDupilumab

Sanofi

Phase 4

California, Florida, Idaho, Illinois, Iowa, Massachusetts, Minnesota, North Carolina

2023-11-29

Active, closed

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445NonSegmental Vitiligo

DrugPovorcitinib

Incyte Corporation

Phase 3

467

Alabama, California, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri

2023-11-29

Recruiting

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

NCT06122077Lung Cancer Diagnosis

Freenome Holdings Inc.

Observational

20,000

California, Connecticut, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts

2023-11-28

Recruiting

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

NCT06212947Hypochondroplasia

BioMarin Pharmaceutical

Observational

400

Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota

2023-11-27

Recruiting

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis

Alcyone Therapeutics, Inc

Not applicable

Arizona, California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio

2023-11-27

By invitation

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

NCT06115642Advanced/Metastatic Malignant Solid Tumors

DrugsHLX43·Serplulimab

Shanghai Henlius Biotech

Phase 1

367

California, District of Columbia, Illinois, Massachusetts, Texas

2023-11-24

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943Lymphatic Malformations

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2/3

232

California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon

2023-11-24

Active, closed

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT06160752Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma

Tyra Biosciences, Inc

Phase 1

California, Massachusetts, Ohio, Texas

2023-11-22

Recruiting

ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

NCT05172973Aortic Valve Insufficiency, Aortic Valve Stenosis

Edwards Lifesciences

Not applicable

200

California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts

2023-11-22

Active, closed

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

NCT06120205Hpv, HPV 16 Infection, HPV Infection, High Risk HPV

Teal Health, Inc.

Not applicable

870

Alabama, California, Colorado, Connecticut, Louisiana, Maryland, Massachusetts, Missouri

2023-11-20

Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma

DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

914

Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota

2023-11-20

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent

DrugMitomycin C

UroGen Pharma Ltd.

Observational

450

California, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts, Michigan

2023-11-17

Active, closed

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329Pre-Exposure Prophylaxis of HIV Infection

DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir

Gilead Sciences

Phase 2

253

Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina

2023-11-17

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsSotorasib·Pembrolizumab

Amgen

Phase 3

750

California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York

2023-11-16

Active, closed

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

NCT06292923Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences LTD

Phase 2

Connecticut, Maryland, Massachusetts, New York, Pennsylvania

2023-11-15

Recruiting

GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial

NCT06141135Infertility, Female

Genomic Prediction Inc.

Not applicable

240

Massachusetts

2023-11-15

Active, closed

A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS

NCT06076499Restless Legs Syndrome

Noctrix Health, Inc.

Observational

325

California, Massachusetts, Missouri, Ohio, Pennsylvania, South Carolina

2023-11-15

Active, closed

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms

DrugDisitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

120

Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan

2023-11-14

By invitation

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

NCT06275620X-Linked Retinitis Pigmentosa

DrugAGTC-501

Beacon Therapeutics

Phase 2

Florida, Massachusetts, Ohio, Oregon, Texas

2023-11-14

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

California, Colorado, Florida, Indiana, Massachusetts, Michigan, New York, Oklahoma

2023-11-14

Active, closed

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907Ulcerative Colitis

DrugUpadacitinib

AbbVie

Phase 3

122

Arizona, Arkansas, California, Colorado, Delaware, Georgia, Illinois, Massachusetts

2023-11-06

Recruiting

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

NCT05901285Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab

Vaxiion Therapeutics

Phase 1

Arizona, Colorado, District of Columbia, Massachusetts, New Hampshire, New Jersey, Ohio

2023-11-02

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer

DrugsFOLFIRI Protocol·Zirabev·Mvasi·Regorafenib

Neonc Technologies, Inc.

Phase 1/2

134

California, Florida, Massachusetts, Tennessee, Texas, Washington

2023-11-01

Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012Relapsed/Refractory Multiple Myeloma

Ichnos Sciences SA

Phase 1

200

California, Florida, Georgia, Illinois, Massachusetts, New York, North Carolina, Tennessee

2023-11-01

Active, closed

A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

NCT06055725Spasticity as Sequela of Stroke

Ipsen

Observational

1,057

California, Florida, Maryland, Massachusetts, Missouri, Nebraska, Nevada, North Carolina

2023-11-01

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Arizona, California, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan

2023-10-31

Active, closed

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332Metastatic Uveal Melanoma

DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy

IDEAYA Biosciences

Phase 2/3

420

Arizona, California, Colorado, Florida, Georgia, Iowa, Massachusetts, Michigan

2023-10-31

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Massachusetts

2023-10-27

Active, closed

Gravitas Feeding Tube System Placement Validation in Neonates

NCT05914064Nasogastric Tube

Gravitas Medical, Inc.

Not applicable

100

California, Georgia, Massachusetts, Rhode Island, Virginia

2023-10-27

Recruiting

Nectero EAST System Clinical Study

NCT06001918Abdominal Aortic Aneurysm

Nectero Medical, Inc.

Phase 2/3

400

Arizona, Colorado, District of Columbia, Florida, Georgia, Illinois, Maine, Massachusetts

2023-10-25

Active, closed

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

114

California, Colorado, District of Columbia, Florida, Illinois, Iowa, Maryland, Massachusetts

2023-10-23

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06067841Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 1

140

California, Florida, Massachusetts, New York, North Carolina, Texas, Washington

2023-10-18

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

DrugsAdagrasib·Cabozantinib

Kura Oncology, Inc.

Phase 1

300

Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota

2023-10-18

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

California, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Nebraska

2023-10-18

Active, closed

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189Lung Cancer

Hummingbird Diagnostics

Observational

2,000

Georgia, Louisiana, Massachusetts, Michigan, New York, Pennsylvania, Texas, Utah

2023-10-18

Recruiting

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

NCT05811364Aortoiliac Occlusive Disease, Peripheral Arterial Disease

W.L.Gore & Associates

Not applicable

244

Arkansas, California, Colorado, Florida, Georgia, Louisiana, Massachusetts, Michigan

2023-10-17

Active, closed

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCT05657301Age-Related Macular Degeneration

DrugKH631

Chengdu Origen Biotechnology Co., Ltd.

Phase 1

Arizona, Illinois, Massachusetts, Nevada, New Jersey, Tennessee, Texas

2023-10-16

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan, Minnesota

2023-10-16

By invitation

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

NCT06315023Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions

Endologix

Observational

450

California, Connecticut, District of Columbia, Florida, Massachusetts, Missouri, New York, Ohio

2023-10-06

Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

NCT05941507Advanced Solid Tumors

LigaChem Biosciences, Inc.

Phase 1/2

300

California, Massachusetts, Michigan, Tennessee, Texas

2023-10-05

Active, closed

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology

NCT06202274Hair Reduction, Tattoo Removal, Wrinkle, Acne

Candela Corporation

Not applicable

500

Florida, Massachusetts

2023-10-04

Active, closed

EndeavorOTC™ Prospective Product Registry

NCT06109051ADHD

Akili Interactive Labs, Inc.

Observational

198

Massachusetts

2023-10-03

Active, closed

GDNF Gene Therapy for Multiple System Atrophy

NCT04680065Multiple System Atrophy

DrugAAV2-GDNF gene therapy

Brain Neurotherapy Bio, Inc.

Phase 1

California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee

2023-10-03

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri, New Mexico

2023-10-02

Recruiting

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367GIST

DrugRipretinib

Deciphera Pharmaceuticals, LLC

Phase 1/2

California, Florida, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon

2023-09-28

By invitation

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

NCT05967351Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.

Phase 3

400

Arkansas, California, Colorado, Florida, Illinois, Iowa, Maryland, Massachusetts

2023-09-27

Active, closed

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677Hereditary Angioedema

DrugNavenibart

Astria Therapeutics, Inc.

Phase 2

Alabama, Arizona, Arkansas, California, Maryland, Massachusetts, Missouri, Ohio

2023-09-26

Active, closed

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866Multiple System Atrophy (MSA)

Ono Pharmaceutical Co., Ltd.

Phase 2

California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Michigan

2023-09-22

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Minnesota

2023-09-21

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Massachusetts

2023-09-21

Recruiting

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

NCT05957536HER-2 Positive Advanced Solid Tumors

D3 Bio (Wuxi) Co., Ltd

Phase 1

128

California, Massachusetts, New York, Texas

2023-09-19

Recruiting

Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens

NCT06034327Myopia, Juvenile Myopia, Myopia Progression

SightGlass Vision, Inc.

Not applicable

150

California, Florida, Georgia, Illinois, Kansas, Massachusetts, Missouri, Ohio

2023-09-18

Active, closed

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071Meibomian Gland Dysfunction, Dry Eye Disease

Candela Corporation

Not applicable

100

Florida, Massachusetts

2023-09-18

Recruiting

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

NCT05821959Sensorineural Hearing Loss, Bilateral

Eli Lilly and Company

Phase 3

California, Iowa, Massachusetts, Ohio, Pennsylvania, Tennessee

2023-09-15

Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer

Iksuda Therapeutics Ltd.

Phase 1

165

California, Massachusetts, Tennessee, Texas

2023-09-14

Active, closed

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis

DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

270

Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri, Nebraska

2023-09-13

Active, closed

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

NCT06018428Alopecia Areata

DrugBempikibart

Q32 Bio Inc.

Phase 2

Arizona, Arkansas, California, Connecticut, Florida, Indiana, Kentucky, Massachusetts

2023-09-12

Active, closed

Cryoablation for Monomorphic Ventricular Tachycardia

NCT05675865Sustained VT

Adagio Medical

Not applicable

206

Arizona, California, Maryland, Massachusetts, Michigan, New York, Ohio, Pennsylvania

2023-09-11

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Alabama, Arizona, California, Georgia, Maryland, Massachusetts, Michigan, Missouri

2023-09-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

Arizona, California, District of Columbia, Maryland, Massachusetts, Michigan, Nevada, New Jersey

2023-09-08

Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

DrugsRMC-9805·Cetuximab

Revolution Medicines, Inc.

Phase 1

604

California, Connecticut, Florida, Maryland, Massachusetts, New York, North Carolina, Ohio

2023-09-07

Recruiting

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT05652686Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

DrugsLurbinectedin·Topotecan·Irinotecan·Etoposide

Phanes Therapeutics

Phase 1/2

203

California, Colorado, Connecticut, Maryland, Massachusetts, Missouri, North Carolina, Oklahoma

2023-09-05

Recruiting

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

NCT06092034Danon Disease

Rocket Pharmaceuticals Inc.

Phase 2

California, Massachusetts, Pennsylvania

2023-09-05

Recruiting

SPEARHEAD-3 Pediatric Study

NCT05642455Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma

USWM CT, LLC

Phase 1/2

California, Maryland, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania

2023-09-01

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269Rheumatoid Arthritis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

420

Arizona, California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, North Carolina

2023-08-31

By invitation

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

NCT05883748Erythropoietic Protoporphyria

Disc Medicine, Inc

Phase 2/3

230

Alabama, California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania

2023-08-31

Recruiting

Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

NCT05361941Periprosthetic Joint Infections

Elute, Inc.

Not applicable

204

California, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Michigan, New York

2023-08-31

Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD

Alexion Pharmaceuticals, Inc.

Observational

200

District of Columbia, Massachusetts, North Carolina, Ohio, Texas, Wisconsin

2023-08-30

Recruiting

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT05798923Pulmonary Hypertension Due to Lung Diseases and Hypoxia

IRulya Therapeutics Inc.

Phase 2

Arizona, Connecticut, Massachusetts, Pennsylvania

2023-08-30

Active, closed

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

NCT05956626Stargardt Disease

Ocugen

Phase 2/3

Arizona, California, Florida, Indiana, Massachusetts, Mississippi, Missouri, North Carolina

2023-08-25

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589Asthma

DrugTezepelumab

AstraZeneca

Phase 3

231

Alabama, Arizona, Arkansas, California, Georgia, Maryland, Massachusetts, Michigan

2023-08-24

Active, closed

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label

DrugsKeytruda·Pembrolizumab

Flare Therapeutics Inc.

Phase 1

120

California, Connecticut, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio

2023-08-24

Active, closed

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

NCT05862324Metastatic Solid Tumor

Triumvira Immunologics, Inc.

Phase 1/2

113

California, Florida, Massachusetts, New York, Ohio, Texas

2023-08-23

Recruiting

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

NCT05878860X-linked Retinoschisis

Atsena Therapeutics Inc.

Phase 3

Arizona, California, Florida, Massachusetts, Michigan, Minnesota, New York, North Carolina

2023-08-22

Active, closed

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471HIV Infections

DrugsVH3810109·Phesgo·Cabotegravir

ViiV Healthcare

Phase 2

185

Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts

2023-08-17

Recruiting

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

NCT05785741Advanced Solid Tumor

DrugsDB-1310·Osimertinib·Trastuzumab·Capecitabine

DualityBio Inc.

Phase 1/2

1,000

California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee

2023-08-17

Active, closed

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

Massachusetts

2023-08-16

Recruiting

mTBI Identification and Monitoring Through Retinal Scanning

NCT06142435Brain Injuries, Traumatic

Rebiscan, Inc.

Observational

Massachusetts

2023-08-15

By invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

NCT05844449Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

174

California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Minnesota, Missouri

2023-08-11

Recruiting

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259Hypertrophic Cardiomyopathy

Tenaya Therapeutics

Phase 1/2

California, Georgia, Massachusetts, Minnesota, Ohio, Oregon, Pennsylvania, Texas

2023-08-10

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Alabama, California, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada

2023-08-08

Active, closed

The BD Liverty™ TIPS Stent Graft Study

NCT05711316Portal Hypertension, TIPS

C. R. Bard

Not applicable

177

California, District of Columbia, Indiana, Kansas, Massachusetts, Missouri, New Jersey, New York

2023-08-08

By invitation

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

NCT05796440Growth Hormone Deficiency

DrugLUM-201

Lumos Pharma

Phase 2

Iowa, Massachusetts, Missouri, South Carolina, Texas, Washington

2023-08-01

Recruiting

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia

Carna Biosciences, Inc.

Phase 1

120

California, Florida, Illinois, Indiana, Maryland, Massachusetts, New York, North Carolina

2023-08-01

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Alabama, California, Massachusetts, Nevada, New Jersey, New York, Ohio, Tennessee

2023-07-31

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

NCT05778188Hypoxic-Ischemic Encephalopathy

DrugRLS-0071

ReAlta Life Sciences, Inc.

Phase 2

Arkansas, California, Florida, Indiana, Kentucky, Massachusetts, Missouri, North Carolina

2023-07-27

Active, closed

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

NCT05680922Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung

Legend Biotech USA Inc

Phase 1

Florida, Kentucky, Massachusetts, New York

2023-07-26

Active, closed

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

NCT05910528Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 2

Alabama, Connecticut, Florida, Massachusetts, Michigan

2023-07-24

Active, closed

Abbott Ventricular Tachycardia PAS

NCT05839873Ventricular Tachycardia

Abbott Medical Devices

Observational

Florida, Indiana, Kansas, Massachusetts, Minnesota, North Carolina, Oklahoma, South Carolina

2023-07-24

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

DrugsINCA33890·ADG126·Folfox·Cetuximab

Incyte Corporation

Phase 1

570

California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas

2023-07-24

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Arkansas, California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts

2023-07-19

Active, closed

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

NCT05819866Cerebral Adrenoleukodystrophy (cALD)

Minoryx Therapeutics, S.L.

Phase 3

California, Maryland, Massachusetts, Minnesota

2023-07-12

Recruiting

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma

AstraZeneca

Phase 1

Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon

2023-07-12

Recruiting

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

NCT05710848Non-muscle-invasive Bladder Cancer

SURGE Therapeutics

Phase 1/2

Arizona, Arkansas, California, Florida, Maryland, Massachusetts, Michigan, Ohio

2023-07-11

Active, closed

Observational Study to Investigate the Use of Sterilized Porcine Placental Tissue in the Treatment of Chronic VLU

NCT06400875Ulcer Venous, Wound Heal

ConvaTec Inc.

Observational

Massachusetts

2023-07-10

Active, closed

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

212

California, Connecticut, Georgia, Idaho, Louisiana, Maryland, Massachusetts, Minnesota

2023-07-07

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

NCT05549258Neuromyelitis Optica Spectrum Disorder

DrugInebilizumab

Amgen

Phase 2

California, Massachusetts, Texas

2023-07-03

Active, closed

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

NCT05781113Multiple Sclerosis

Celestra Health Systems

Observational

Massachusetts

2023-07-01

Active, closed

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05925049Multiple Sclerosis

DrugNatalizumab

Biogen

Observational

400

Massachusetts

2023-06-30

Active, closed

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

NCT05911763Hemophilia A

DrugEfanesoctocog alfa

Sanofi

Observational

200

Arizona, California, Colorado, Florida, Illinois, Indiana, Iowa, Massachusetts

2023-06-30

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT05785754Advanced or Metastatic Solid Tumors

DrugsDCSZ11·Tebentafusp·Doxorubicin·Pembrolizumab

DynamiCure Biotechnology

Phase 1

320

Alabama, Arizona, Colorado, Connecticut, Florida, Maryland, Massachusetts, Minnesota

2023-06-28

Active, closed

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

DrugsIrinotecan·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

123

California, Massachusetts, New York, Texas

2023-06-27

Recruiting

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Regeneron Pharmaceuticals

Phase 1/2

California, Florida, Massachusetts, New York, Ohio, Washington, Wisconsin

2023-06-27

Active, closed

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

NCT05644561Generalized Myasthenia Gravis, gMG

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

California, Massachusetts, North Carolina, Pennsylvania

2023-06-24

Active, closed

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms

DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

390

California, Colorado, Georgia, Indiana, Massachusetts, Missouri, New York, North Carolina

2023-06-23

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan

2023-06-22

Active, closed

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT06087458Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration

DrugVOY-101

Perceive Biotherapeutics, Inc.

Phase 1/2

Arizona, California, Massachusetts, Missouri, New Jersey, Oregon, South Dakota, Texas

2023-06-21

Active, closed

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

NCT05893498Percutaneous Coronary Intervention

CathWorks Ltd.

Not applicable

1,924

California, Florida, Georgia, Illinois, Kansas, Kentucky, Maryland, Massachusetts

2023-06-21

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Dexamethasone

GlaxoSmithKline

Phase 1/2

123

Arizona, California, Florida, Massachusetts, Michigan, North Carolina, Ohio, Tennessee

2023-06-14

Active, closed

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

MeiraGTx, LLC

Phase 2

290

Arizona, California, Florida, Iowa, Maryland, Massachusetts, Michigan, Missouri

2023-06-13

Active, closed

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

NCT05898620Rett Syndrome

Neurogene Inc.

Phase 3

Alabama, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York

2023-06-13

Active, closed

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

NCT05887492Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma

DrugsKeytruda·Pembrolizumab

Tango Therapeutics, Inc.

Phase 1/2

126

California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, Texas

2023-06-12

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Arizona, California, Colorado, Illinois, Massachusetts, New Jersey, New York, Ohio

2023-06-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan

2023-06-07

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

California, Colorado, Illinois, Indiana, Massachusetts, Minnesota, Nevada, New York

2023-06-07

Active, closed

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

NCT05848739Colon Cancer, Metastatic Colon Cancer

DrugsFOLFIRI & bevacizumab·Fruquintinib·Folfox

Sapience Therapeutics

Phase 1

130

Alabama, California, Colorado, Louisiana, Massachusetts, Michigan, New York, North Carolina

2023-06-05

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island

2023-06-05

Recruiting

Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression

NCT06017622Acute Cannabis-induced CNS Depression

Anebulo Pharmaceuticals

Observational

Massachusetts, Ohio, Oregon

2023-06-01

Active, closed

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.

Phase 3

148

Arkansas, California, Florida, Illinois, Maryland, Massachusetts, Missouri, New York

2023-05-31

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

California, Colorado, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri

2023-05-31

Active, closed

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

NCT05879744NHL, NHL, Relapsed, Adult

DrugCLN-978

Cullinan Therapeutics Inc.

Phase 1

Alabama, California, Georgia, Massachusetts, New Jersey, Texas

2023-05-31

Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831Locally Advanced Solid Tumor

DrugsTNG462·Keytruda·Pembrolizumab

Tango Therapeutics, Inc.

Phase 1/2

225

California, Colorado, Florida, Illinois, Massachusetts, Michigan, New York, Tennessee

2023-05-26

Active, closed

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

NCT05885464Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia

Beam Therapeutics Inc.

Phase 1/2

California, Colorado, Illinois, Kansas, Massachusetts, Ohio, Oregon, Pennsylvania

2023-05-25

Active, closed

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

NCT05408546Pulmonary Embolism

DrugTS23

Translational Sciences, Inc.

Phase 2

Arizona, California, Georgia, Maryland, Massachusetts, Michigan, North Carolina, Ohio

2023-05-24

Active, closed

Study of PYX-106 in Solid Tumors

NCT05718557Solid Tumor

Pyxis Oncology, Inc

Phase 1

Arizona, California, Colorado, Georgia, Illinois, Massachusetts, Ohio, Rhode Island

2023-05-23

Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor

DrugsLonsurf·MFOLFOX6·Trifluridine/Tipiracil·Avastin

Parabilis Medicines, Inc.

Phase 1/2

619

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts

2023-05-23

Recruiting

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

NCT05737121Interstitial Cystitis, Bladder Pain Syndrome

DrugsVNX001·Heparin·Lidocaine

Vaneltix Pharma, Inc.

Phase 2

120

California, Florida, Georgia, Louisiana, Massachusetts, Nevada, New York, North Carolina

2023-05-22

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Arizona, California, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma

2023-05-20

Recruiting

MASA Valve Early Feasibility Study

NCT05452720Tetrology of Fallot, Pulmonary Stenosis, Truncus Arteriosus, Transposition of Great Vessels

PECA Labs

Not applicable

Illinois, Massachusetts, Ohio, Pennsylvania, Texas

2023-05-18

Active, closed

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy

Impulse Dynamics

Not applicable

300

Arizona, California, Connecticut, Florida, Iowa, Kansas, Kentucky, Massachusetts

2023-05-17

Active, closed

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

NCT05791201Type 1 Diabetes

Vertex Pharmaceuticals Incorporated

Phase 1/2

Florida, Illinois, Massachusetts, Pennsylvania, Wisconsin

2023-05-16

Active, closed

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

NCT05552469Myeloid Diseases

Novartis Pharmaceuticals

Phase 1

California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York, Tennessee

2023-05-08

Active, closed

Phase III Study of AK112 for NSCLC Patients

NCT06396065Non-Squamous Non-small Cell Lung Cancer

DrugsIvonescimab·Pemetrexed·Carboplatin

Summit Therapeutics

Phase 3

420

California, Colorado, Florida, Louisiana, Maine, Maryland, Massachusetts, Minnesota

2023-05-04

Active, closed

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis

DrugDupilumab

Regeneron Pharmaceuticals

Phase 2

Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts

2023-05-03

Recruiting

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05850689Major Depressive Disorder

DrugLumateperone

Intra-Cellular Therapies, Inc.

Phase 3

470

Alabama, California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri

2023-05-02

Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation

Omeros Corporation

Phase 2

California, Florida, Massachusetts, Missouri, New York, Texas, Washington

2023-05-01

Active, closed

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756Hypothalamic Obesity

DrugSetmelanotide

Rhythm Pharmaceuticals, Inc.

Phase 3

143

Alabama, California, Colorado, Florida, Illinois, Iowa, Massachusetts, Minnesota

2023-04-26

Active, closed

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

NCT05714514Kidney Transplantation in Highly Sensitized Patients

DrugImlifidase

Hansa Biopharma AB

Observational

Alabama, California, Illinois, Maryland, Massachusetts, Missouri, New Jersey, New York

2023-04-21

Recruiting

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

NCT05765175Tachycardia, Ventricular

Varian, a Siemens Healthineers Company

Not applicable

380

California, Connecticut, Massachusetts, Minnesota, Missouri, Ohio, Pennsylvania, South Carolina

2023-04-21

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

NCT05685173B-cell Non-Hodgkins Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 1

107

California, Kentucky, Massachusetts, New Jersey, New York, Texas

2023-04-20

Recruiting

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139Breast Cancer, Solid Tumors, Adult

DrugsTersolisib·Imlunestrant·Tamoxifen·Exemestane

Eli Lilly and Company

Phase 1/2

880

California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts

2023-04-17

Active, closed

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R

Elicio Therapeutics

Phase 1/2

158

Arizona, California, Colorado, Florida, Georgia, Iowa, Louisiana, Massachusetts

2023-04-14

Recruiting

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

NCT05804318Prostate Cancer

Varian, a Siemens Healthineers Company

Not applicable

132

California, Massachusetts, Missouri, Pennsylvania

2023-04-13

Active, closed

Study to Evaluate the Safety and Effectiveness of GP0116

NCT05987163Skin Manifestations

Galderma R&D

Not applicable

186

California, Connecticut, Florida, Georgia, Louisiana, Massachusetts, Michigan, New York

2023-04-12

Active, closed

Promising ROd-cone DYstrophy Gene therapY

NCT05748873Retinitis Pigmentosa

SparingVision

Phase 1/2

Florida, Massachusetts, Oregon, Pennsylvania, Texas

2023-04-12

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia

Schrödinger, Inc.

Phase 1

Arizona, Delaware, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio

2023-04-10

Active, closed

Open Label Optimization Study

NCT05819021Major Depressive Disorder

Magnus Medical

Observational

1,000

California, Massachusetts, New York, Washington

2023-04-06

Active, closed

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

NCT05683457Cytomegalovirus Infection

ModernaTX, Inc.

Phase 2

Massachusetts, Missouri, Washington

2023-04-05

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

NCT05816382Narcolepsy Type 1

DrugTAK-861

Takeda

Phase 2/3

500

Alabama, California, Colorado, Florida, Georgia, Massachusetts, Michigan, North Carolina

2023-04-05

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Arizona, California, Colorado, Illinois, Maryland, Massachusetts, Michigan, Minnesota

2023-04-03

Active, closed

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

NCT05725018Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB

DrugPz-cel

Abeona Therapeutics, Inc

Phase 3

California, Massachusetts

2023-04-02

Recruiting

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

DrugsAbemaciclib·Fulvestrant

Incyclix Bio

Phase 1/2

150

Florida, Georgia, Indiana, Massachusetts, Michigan, New York, North Carolina, Ohio

2023-03-28

Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma

DrugsGV20-0251·Keytruda·Pembrolizumab

GV20 Therapeutics

Phase 1/2

365

California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Michigan, New York

2023-03-23

Active, closed

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

NCT05669482KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic

DrugsAvutometinib (VS-6766) and defactinib·Gemcitabine and nab-paclitaxel

Verastem, Inc.

Phase 1/2

California, Illinois, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Utah

2023-03-22

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Colorado, Florida, Massachusetts, Virginia

2023-03-20

Active, closed

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

NCT04485949Glioblastoma

Imvax

Phase 2

Florida, Massachusetts, Michigan, New Hampshire, New Jersey, New York, North Carolina, Ohio

2023-03-20

Recruiting

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

NCT05482893Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer

DrugsNalirifox·Folfirinox·Trifluridine/Tipiracil·Abraxane

Phanes Therapeutics

Phase 1/2

350

California, Colorado, Iowa, Kentucky, Massachusetts, North Carolina, Pennsylvania, Texas

2023-03-15

Active, closed

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

DrugPovetacicept

Alpine Immune Sciences, Inc.

Phase 1/2

Arizona, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Missouri

2023-03-15

Recruiting

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117Solid Tumor, Advanced Solid Tumor

DrugPYX-201

Pyxis Oncology, Inc

Phase 1

330

Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri

2023-03-14

Recruiting

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056Netherton Syndrome

DrugQRX003- Lotion

Quoin Pharmaceuticals

Phase 2/3

California, Indiana, Massachusetts, Texas

2023-03-14

Recruiting

An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

NCT05757141Vanishing White Matter Disease

DrugFosigotifator

Calico Life Sciences LLC

Phase 1/2

Massachusetts, Pennsylvania, Utah

2023-03-13

Active, closed

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer

DrugsGimistotug·Alcestobart·Nab-paclitaxel·Pemetrexed

BeiGene

Phase 2

400

California, Massachusetts, New York, Oregon, Texas

2023-03-07

Active, closed

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

NCT05606614Rett Syndrome

Taysha Gene Therapies, Inc.

Phase 3

California, Illinois, Maryland, Massachusetts, Missouri, Texas

2023-03-06

Recruiting

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

NCT05327062Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block

XSpline S.p.A.

Not applicable

150

Illinois, Massachusetts, North Carolina

2023-03-06

Active, closed

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis

W.L.Gore & Associates

Not applicable

165

California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan, New Jersey

2023-03-02

Active, closed

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

NCT05573555Breast Cancer

DrugsVepdegestrant·Ribociclib

Pfizer

Phase 1/2

California, Florida, Illinois, Massachusetts, Missouri

2023-03-01

Active, closed

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases

DrugsDonanemab·Dexamethasone

Eli Lilly and Company

Phase 3

1,175

Arizona, California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Rhode Island

2023-02-28

Active, closed

Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application

NCT05094089Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral

W.L.Gore & Associates

Observational

320

Georgia, Massachusetts, Michigan, New Mexico, New York, North Carolina, South Carolina, Virginia

2023-02-24

Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932Multiple Myeloma, Myeloma, Myeloma Multiple

DrugsMezigdomide·Carfilzomib·Pomalidomide·Dexamethasone

K36 Therapeutics, Inc.

Phase 1

165

California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina

2023-02-22

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, Missouri, Nebraska

2023-02-21

Active, closed

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

NCT05630755HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

514

Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri

2023-02-17

Active, closed

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

NCT05690386Turner Syndrome

DrugSomatropin

Ascendis Pharma Endocrinology Division A/S

Phase 2

California, Colorado, Florida, Georgia, Idaho, Illinois, Massachusetts, Minnesota

2023-02-15

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418HR+/HER2-negative Breast Cancer

DrugsRibociclib·Palbociclib·Fulvestrant

Totus Medicines

Phase 1

241

Illinois, Massachusetts, Nevada, Pennsylvania, Tennessee, Texas, Virginia

2023-02-15

Active, closed

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940Treatment Resistant Depression

DrugPsilocybin

COMPASS Pathways

Phase 3

572

Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota

2023-02-14

Active, closed

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

NCT05621317Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases

Aravax Pty Ltd

Phase 2

Arkansas, California, Georgia, Indiana, Maryland, Massachusetts, North Carolina

2023-02-09

Active, closed

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

226

Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Massachusetts

2023-02-03

Active, closed

Pilot/Pivotal Study of DBS+Rehab After Stroke

NCT05701280Stroke, Upper Extremity Paresis

Enspire DBS Therapy, Inc.

Not applicable

202

Arizona, Maryland, Massachusetts, Minnesota, New York, Ohio, Pennsylvania, Rhode Island

2023-02-03

By invitation

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

NCT05718570Adult Growth Hormone Deficiency

DrugSomapacitan

Novo Nordisk A/S

Observational

400

Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts

2023-02-03

Active, closed

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219Primary Immune Thrombocytopenia

DrugsEltrombopag·Ianalumab

Novartis Pharmaceuticals

Phase 3

152

Arizona, Colorado, Illinois, Massachusetts, Michigan, Montana, New York

2023-02-02

Recruiting

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

NCT06311708Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics

Observational

200

California, Colorado, Maryland, Massachusetts, Minnesota, New York, Ohio, South Carolina

2023-01-31

Active, closed

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

NCT05733546Major Depressive Disorder

DrugPsilocybin

COMPASS Pathways

Phase 2

102

California, Florida, Maryland, Massachusetts, Texas

2023-01-30

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

California, Colorado, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York

2023-01-16

Active, closed

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

513

California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan, Minnesota

2023-01-12

Active, closed

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugIMGN151

AbbVie

Phase 1

256

Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Mississippi

2023-01-11

Recruiting

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

DrugsElacestrant·Exemestane·Everolimus·Abemaciclib

Ellipses Pharma

Phase 1/2

Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia

2023-01-11

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Alabama, California, Florida, Georgia, Idaho, Maryland, Massachusetts, Minnesota

2023-01-10

Active, closed

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

NCT05662241IgG4 Related Disease

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 3

194

California, Florida, Georgia, Massachusetts, Michigan

2023-01-09

Active, closed

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

NCT05506943Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer

DrugPaclitaxel

Compass Therapeutics

Phase 2/3

168

Arizona, California, Colorado, Florida, Illinois, Louisiana, Maryland, Massachusetts

2023-01-09

Active, closed

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

NCT05680818Autosomal Dominant Hypocalcemia (ADH)

DrugEncaleret

Calcilytix Therapeutics, Inc., a BridgeBio company

Phase 3

California, Colorado, Indiana, Maryland, Massachusetts, Minnesota, New York, North Carolina

2023-01-06

Active, closed

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck

DrugsEtakafusp alfa·Keytruda·Pembrolizumab

Asher Biotherapeutics, Inc.

Phase 1

552

California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey

2023-01-04

Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm

DrugSTAR0602

Marengo Therapeutics, Inc.

Phase 1/2

366

California, Florida, Kansas, Maryland, Massachusetts, Michigan, Ohio, Tennessee

2023-01-04

Active, closed

SpermQT Prospective Observational Trial

NCT05966883Male Infertility

Inherent Biosciences

Observational

1,000

California, Colorado, Connecticut, Massachusetts, Texas, Washington

2023-01-01

Active, closed

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 2

California, Colorado, Connecticut, Florida, Georgia, Louisiana, Maryland, Massachusetts

2022-12-29

Active, closed

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.

NCT05592002Sleep Apnea, Obstructive

Nyxoah S.A.

Not applicable

124

Colorado, Florida, Indiana, Iowa, Kansas, Massachusetts, New York, Pennsylvania

2022-12-28

By invitation

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 2/3

150

Alabama, Arkansas, California, Colorado, Maryland, Massachusetts, Michigan, Missouri

2022-12-28

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Massachusetts

2022-12-23

Recruiting

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT05313165Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease

LimFlow, Inc.

Not applicable

100

California, Connecticut, Florida, Illinois, Massachusetts, Missouri, New Hampshire, New Jersey

2022-12-22

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania

2022-12-21

By invitation

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

NCT05334784High-Risk Percutaneous Coronary Intervention

Abiomed Inc.

Not applicable

856

Arizona, Arkansas, California, Florida, Georgia, Louisiana, Massachusetts, Michigan

2022-12-20

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Arizona, Florida, Georgia, Kansas, Kentucky, Massachusetts, Minnesota, Missouri

2022-12-19

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 2

Arkansas, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas

2022-12-16

Active, closed

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

NCT05675449Multiple Myeloma

DrugsElranatamab·Carfilzomib

Pfizer

Phase 1

Arkansas, California, Florida, Georgia, Iowa, Maryland, Massachusetts, New Jersey

2022-12-14

Active, closed

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

NCT05529316Advanced Melanoma

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

150

Arizona, California, Connecticut, District of Columbia, Massachusetts, New Jersey

2022-12-12

Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugsErythromycin·Rina-S·Itraconazole·Bevacizumab

Genmab

Phase 1/2

952

Arizona, California, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan

2022-12-07

Recruiting

[18F]PI-2620 Phase 3 Histopathological Study

NCT05641688Alzheimer Disease

Lantheus Biosciences Ltd.

Phase 3

200

Arizona, California, Florida, Massachusetts, Nebraska, New Hampshire, New York, North Carolina

2022-12-01

Active, closed

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer

DrugPF-07799933

Pfizer

Phase 1

148

Alabama, Arkansas, California, Florida, Louisiana, Massachusetts, Michigan, New Jersey

2022-11-30

Active, closed

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044Metastatic Colorectal Cancer

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

234

Arizona, California, Colorado, Delaware, Florida, Massachusetts, Michigan, New Jersey

2022-11-30

Active, closed

Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

NCT05457010Acute Myeloid Leukemia, Myelodysplastic Syndromes

DrugsSPRX002·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 1

California, Maryland, Massachusetts, New York, Texas

2022-11-28

Active, closed

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

NCT05609578Advanced NSCLC, Metastatic Lung Cancer

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

California, Colorado, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota

2022-11-22

Active, closed

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma

DrugTYRA-300

Tyra Biosciences, Inc

Phase 1/2

310

Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington

2022-11-22

Active, closed

A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

NCT05295290Myocarditis

Pfizer

Phase 4

319

California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Louisiana, Massachusetts

2022-11-21

Active, closed

RESPONDER-HF Trial

NCT05425459Heart Failure, Heart Failure, Diastolic

Corvia Medical

Not applicable

750

Arizona, California, Delaware, Florida, Georgia, Illinois, Louisiana, Massachusetts

2022-11-17

Recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

NCT05533775Mature B-Cell Non-Hodgkin Lymphoma

DrugsIfosfamide·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

Alabama, California, Maryland, Massachusetts, Missouri, New York, Ohio

2022-11-16

Active, closed

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

NCT05546580Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

DrugsXospata·Gilteritinib

Oryzon Genomics S.A.

Phase 1

Arizona, Florida, Maryland, Massachusetts, New Jersey, New York, North Carolina, Oregon

2022-11-14

By invitation

EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study

NCT05610787Heart Failure, Transplant; Failure, Heart, Congenital Heart Disease

Berlin Heart, Inc

Not applicable

California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Missouri

2022-11-14

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

California, District of Columbia, Florida, Kansas, Maryland, Massachusetts, Missouri, New Jersey

2022-11-11

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Arizona, California, District of Columbia, Florida, Georgia, Iowa, Maryland, Massachusetts

2022-11-08

Active, closed

The MIRIA Acne Scar Study

NCT05597267Acne Scars - Mixed Atrophic and Hypertrophic

AVAVA, Inc.

Not applicable

Florida, Massachusetts, New York

2022-11-04

Active, closed

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

NCT05473910AML, MDS

DrugTSC-101

TScan Therapeutics, Inc.

Phase 1

310

California, Colorado, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan

2022-11-01

Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420B-cell Non-Hodgkin Lymphoma (B-NHL)

DrugAlemtuzumab

Cellectis S.A.

Phase 1/2

Illinois, Massachusetts, New Jersey, Texas

2022-11-01

Active, closed

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

NCT05367960Fragile X Syndrome

Tetra Discovery Partners

Phase 3

314

California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts

2022-11-01

Active, closed

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

NCT05585320Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)

DrugsModified FOLFIRINOX·Dabrafenib·Pembrolizumab

Immuneering Corporation

Phase 1/2

209

Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, New York

2022-10-31

Recruiting

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941Pneumonia

Pfizer

Observational

12,500

California, Connecticut, District of Columbia, Georgia, Kentucky, Louisiana, Maryland, Massachusetts

2022-10-27

Active, closed

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial

DrugsKeytruda·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

126

Massachusetts, New York, Pennsylvania, Tennessee

2022-10-26

Recruiting

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT05536141Clear Cell Renal Cell Carcinoma, Solid Tumors

DrugsCasdatifan·Zimberelimab·Cabozantinib·Ipilimumab

Arcus Biosciences, Inc.

Phase 1

362

Alabama, California, Florida, Georgia, Kentucky, Louisiana, Maryland, Massachusetts

2022-10-26

Active, closed

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer

DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Massachusetts, New York

2022-10-24

Active, closed

The MONARCH Case Series Study: SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain

NCT05491915Cervicogenic Headache, Occipital Neuralgia

SPR Therapeutics, Inc.

Not applicable

California, Massachusetts, Minnesota, North Carolina, Texas, Utah

2022-10-24

Active, closed

Abbott Atrial Fibrillation Post Approval Study

NCT05434650Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia

Abbott Medical Devices

Observational

200

Alabama, Arkansas, California, Georgia, Louisiana, Massachusetts, Michigan, Mississippi

2022-10-21

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma

DrugsTecentriq·Atezolizumab·Keytruda·Pembrolizumab

Genentech, Inc.

Phase 1

165

California, Colorado, Florida, Georgia, Massachusetts, Missouri, New Jersey, Tennessee

2022-10-20

Active, closed

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510Pulmonary Arterial Hypertension

DrugTreprostinil

United Therapeutics

Phase 4

Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Massachusetts

2022-10-20

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

Arkansas, Florida, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina

2022-10-20

Recruiting

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

NCT05547321Advanced Solid Tumor

DrugsOMTX705·Tislelizumab·Pembrolizumab

Oncomatryx Biopharma S.L.

Phase 1

150

Massachusetts

2022-10-20

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354Multiple Myeloma

DrugsBMS-986158·Tazemetostat·Mezigdomide·Trametinib

Bristol-Myers Squibb

Phase 1/2

260

Alabama, Maryland, Massachusetts, New Jersey, New York

2022-10-18

Active, closed

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

NCT05476497Peanut Allergy

Allergy Therapeutics

Phase 1

Arizona, Florida, Kansas, Massachusetts, Minnesota, Missouri, New York, Ohio

2022-10-17

Active, closed

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244Multiple Myeloma

DrugsCevostamab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

Colorado, Florida, Maryland, Massachusetts, Minnesota, New York, Tennessee, Utah

2022-10-17

Active, closed

A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

NCT05981092Cardiomyopathy, Dilated, Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)

Alexion Pharmaceuticals, Inc.

Observational

California, Colorado, Massachusetts, Minnesota, New York, Pennsylvania

2022-10-14

Recruiting

M-Vizion™ Macroscopic Radiographic Study

NCT05721859Revision Hip Arthroplasty

Medacta USA

Observational

Illinois, Massachusetts, New Hampshire, North Carolina, Pennsylvania, Utah

2022-10-12

Active, closed

Study of Oral MRT-2359 in Selected Cancer Patients

NCT05546268NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL

DrugMRT-2359

Monte Rosa Therapeutics, Inc

Phase 1/2

174

Arizona, California, Connecticut, Kansas, Massachusetts, Michigan, Missouri, New York

2022-10-12

Active, closed

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903Leukemia, Myeloid, Acute

DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine

Janssen Research & Development, LLC

Phase 1

196

Alabama, California, Massachusetts, New York, North Carolina, Texas

2022-10-04

Active, closed

RNS System LGS Feasibility Study

NCT05339126Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures

NeuroPace

Phase 2

Alabama, California, Georgia, Massachusetts, New York

2022-10-04

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

California, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan, New York

2022-09-30

Recruiting

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

NCT05744466Psoriasis

DrugsApremilast·Deucravacitinib

Bristol-Myers Squibb

Observational

1,500

Massachusetts

2022-09-30

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts

2022-09-28

Recruiting

A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives

NCT05794217Rare Diseases

Sanguine Biosciences

Observational

20,000

Massachusetts

2022-09-28

Active, closed

A Retrospective Assessment of OviTex PRS (OviTex)

NCT05736848Reconstructive Surgical Procedures

Tela Bio Inc

Observational

200

Florida, Georgia, Massachusetts, Michigan, New Jersey, New York, South Carolina, Texas

2022-09-27

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis

DrugSatralizumab

Hoffmann-La Roche

Phase 3

122

Alabama, California, Colorado, District of Columbia, Massachusetts, Minnesota, New York, Ohio

2022-09-27

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Colorado, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan, Missouri

2022-09-23

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

California, Florida, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania, Tennessee

2022-09-22

Active, closed

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

NCT05409989Intracranial Aneurysm

Microvention-Terumo, Inc.

Not applicable

154

Florida, Hawaii, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts

2022-09-20

Active, closed

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

DrugElironrasib

Revolution Medicines, Inc.

Phase 1

222

Arkansas, California, Florida, Maryland, Massachusetts, New York, Tennessee, Texas

2022-09-19

Active, closed

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AstraZeneca

Phase 3

607

Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Missouri, New York

2022-09-12

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York

2022-09-06

Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697Advanced Solid Tumors

DrugsIpilimumab·Nivolumab·Pembrolizumab

ModernaTX, Inc.

Phase 1/2

361

California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Missouri

2022-09-01

Active, closed

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NCT05508906Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer

DrugsPalazestrant·Atirmociclib·Alpelisib·Everolimus

Olema Pharmaceuticals, Inc.

Phase 1

190

Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota

2022-08-31

Active, closed

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

NCT05387837Neovascular Age-related Macular Degeneration, Diabetic Macular Edema

DrugAflibercept

Ashvattha Therapeutics, Inc.

Phase 2

California, Illinois, Indiana, Maryland, Massachusetts, Missouri, New Jersey, Pennsylvania

2022-08-31

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

California, Illinois, Massachusetts, Michigan, Ohio, Oregon, Tennessee, Texas

2022-08-31

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

NCT05271409Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

DrugSatralizumab

Hoffmann-La Roche

Phase 3

132

Alabama, California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan

2022-08-30

Active, closed

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

NCT05456880Sickle Cell Disease

Beam Therapeutics Inc.

Phase 1/2

Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri

2022-08-30

Active, closed

Development of a Self-collection Device for Cervical Cancer Screening

NCT05669911Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus

Teal Health, Inc.

Not applicable

235

California, Colorado, Louisiana, Massachusetts, Texas, Wisconsin

2022-08-28

Recruiting

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

NCT05523947HER2-Positive Solid Tumor

Yuhan Corporation

Phase 1/2

147

Massachusetts, Tennessee

2022-08-26

Recruiting

A Prospective Sub-Study of the Global Hypophosphatasia Registry

NCT05234567Hypophosphatasia

DrugAsfotase alfa

Alexion Pharmaceuticals, Inc.

Observational

Connecticut, Illinois, Massachusetts, Missouri, New York, Ohio, Pennsylvania, Tennessee

2022-08-25

Active, closed

Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

NCT04839705Wide Neck Bifurcation Intracranial Aneurysms

Microvention-Terumo, Inc.

Not applicable

195

Florida, Hawaii, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts

2022-08-24

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Arizona, California, Colorado, Florida, Hawaii, Massachusetts, New York, North Carolina

2022-08-24

Active, closed

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

NCT04752813Glioblastoma, Glioblastoma Multiforme

DrugTemozolomide

BPGbio

Phase 2

California, Massachusetts, New Jersey, New York, Texas, Virginia

2022-08-22

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

California, Georgia, Indiana, Massachusetts, Michigan, Minnesota, New York, North Carolina

2022-08-17

Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

NCT05377996Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer

Day One Biopharmaceuticals, Inc.

Phase 1/2

360

Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota

2022-08-15

Active, closed

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883Duchenne Muscular Dystrophy (DMD)

DrugZeleciment Rostudirsen

Dyne Therapeutics

Phase 1/2

California, Colorado, Georgia, Massachusetts, Ohio, Oregon, Pennsylvania, Utah

2022-08-12

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

NCT05468697Renal Cell Carcinoma

DrugsBelzutifan·Palbociclib

Merck Sharp & Dohme LLC

Phase 1/2

District of Columbia, Illinois, Massachusetts, Utah

2022-08-10

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

California, Florida, Georgia, Illinois, Kansas, Massachusetts, New Mexico, New York

2022-08-04

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Florida, Illinois, Massachusetts, Missouri, New York, Oregon, Pennsylvania, Texas

2022-08-03

Recruiting

LYL273 for Patients With Relapsed or Refractory mCRC

NCT05319314Colorectal Cancer

Lyell Immunopharma, Inc.

Phase 1/2

155

California, Colorado, Massachusetts

2022-08-01

Active, closed

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

NCT05389215Idiopathic Pulmonary Fibrosis

Daewoong Pharmaceutical Co. LTD.

Phase 2

102

Arizona, California, Illinois, Kansas, Massachusetts, Michigan, Missouri, North Carolina

2022-07-29

Active, closed

Noninterventional Study Evaluating Parkinson's Disease Diary Use

NCT05363046Parkinson's Disease

BlueRock Therapeutics

Observational

194

Arizona, California, Colorado, Florida, Illinois, Kansas, Kentucky, Massachusetts

2022-07-29

Recruiting

Brain Stimulation for Severe Depression

NCT05393622Depression Severe

Inner Cosmos Inc

Not applicable

Massachusetts, Missouri

2022-07-28

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsZilovertamab vedotin·Nemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

189

Alaska, Arizona, Colorado, Illinois, Kansas, Kentucky, Maryland, Massachusetts

2022-07-21

Active, closed

SP Thoracic IDE Study

NCT05150210Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis

Intuitive Surgical

Not applicable

California, Massachusetts, New York, North Carolina, Texas

2022-07-20

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

NCT07150091Multiple Myeloma

DrugsNirogacestat·Belantamab mafodotin·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 1/2

Massachusetts

2022-07-19

Recruiting

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

NCT04634357Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer

Eureka Therapeutics Inc.

Phase 1/2

California, Massachusetts

2022-07-19

Recruiting

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

NCT06426628Pulmonary Nodule, Solitary, Lung Cancer

Veracyte, Inc.

Observational

2,400

Connecticut, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland, Massachusetts

2022-07-18

Active, closed

Assess Safety and Efficacy of VAD044 in HHT Patients

NCT05406362Hereditary Hemorrhagic Telangiectasia (HHT)

DrugEngasertib

Vaderis Therapeutics AG

Phase 1/2

Massachusetts

2022-07-18

Active, closed

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

NCT05396885Multiple Myeloma

DrugAnitocabtagene Autoleucel

Kite, A Gilead Company

Phase 2

136

Arizona, Arkansas, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts

2022-07-15

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114Hereditary Angioedema

DrugDonidalorsen

Ionis Pharmaceuticals, Inc.

Phase 3

154

Arizona, California, Florida, Kansas, Massachusetts, Michigan, Missouri, North Carolina

2022-07-13

Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma

DrugDibotatug

Dren Bio

Phase 1/2

200

Alabama, California, Connecticut, Florida, Massachusetts, New York, Ohio, Pennsylvania

2022-07-13

Active, closed

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell

MacroGenics

Phase 1

130

Colorado, Maryland, Massachusetts, Michigan, Missouri, North Carolina, Texas

2022-07-13

Recruiting

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340Urinary Tract Infections

DrugTMP/SMX

Locus Biosciences

Phase 2

318

California, Florida, Massachusetts, Missouri, North Carolina

2022-07-13

By invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827Age Related Macular Degeneration (AMD)

Gyroscope Therapeutics Limited

Phase 2

225

California, Colorado, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts

2022-07-12

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Alaska, Arkansas, California, Florida, Georgia, Idaho, Maryland, Massachusetts

2022-07-08

Active, closed

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634Myositis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2

Arizona, California, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan

2022-07-05

Active, closed

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733Biliary Atresia

DrugOdevixibat

Albireo, an Ipsen Company

Phase 3

180

Colorado, Georgia, Indiana, Massachusetts, Missouri, New York, Ohio, Washington

2022-07-05

Active, closed

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma

DrugsPF-07799933·Binimetinib·Erbitux·Midazolam

Pfizer

Phase 1

103

Arkansas, Colorado, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio

2022-07-05

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Binimetinib·Encorafenib·Zirabev

Pfizer

Phase 4

210

Arizona, Georgia, Massachusetts, Minnesota, Missouri, New Jersey, New York, North Carolina

2022-07-05

Active, closed

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

NCT05415072Metastatic Uveal Melanoma

Novartis Pharmaceuticals

Phase 1/2

Massachusetts, New York

2022-07-04

Recruiting

NEO100 and High-Grade Meningioma

NCT05023018Residual, Progressive or Recurrent Grade II or III Meningioma

DrugPerillyl alcohol

Neonc Technologies, Inc.

Phase 2

California, Massachusetts, Texas

2022-07-01

By invitation

Pre-hospital Ventilation Clinical Study

NCT05604430Altered Mental Status, Sepsis, Heart Failure, Hemorrhage

Zoll Medical Corporation

Observational

500

Connecticut, Louisiana, Massachusetts, Texas, Washington

2022-06-30

Active, closed

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

237

Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts

2022-06-27

Active, closed

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

NCT05285553Myopia

CooperVision, Inc.

Not applicable

900

Alabama, California, Florida, Illinois, Indiana, Kansas, Massachusetts, Minnesota

2022-06-25

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594Advanced Solid Malignancies

DrugsPalacaparib·Dato-DXd·Trastuzumab deruxtecan·Temozolomide

AstraZeneca

Phase 1/2

695

California, Illinois, Massachusetts, New York, Oregon, Texas, Virginia

2022-06-24

Recruiting

Comprehensive Outcomes for After Cancer Health

NCT05349227Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer

Pack Health

Not applicable

625

Florida, Massachusetts, Nebraska, New York, Ohio, Texas

2022-06-23

Active, closed

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

NCT05346354Neuromyelitis Optica Spectrum Disorder

DrugsUltomiris·Ravulizumab

Alexion Pharmaceuticals, Inc.

Phase 2/3

District of Columbia, Florida, Massachusetts, North Carolina, Pennsylvania

2022-06-23

Active, closed

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438Netherton Syndrome

DrugQRX003- Lotion

Quoin Pharmaceuticals

Phase 2/3

California, Indiana, Massachusetts, South Carolina, Texas

2022-06-23

Active, closed

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

NCT05126758Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases

DrugDeramiocel

Capricor Inc.

Phase 3

106

Arizona, Arkansas, California, Colorado, Georgia, Illinois, Iowa, Massachusetts

2022-06-22

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease

AC Immune SA

Phase 1/2

304

Arizona, Florida, Indiana, Kansas, Massachusetts, Missouri, North Carolina, Tennessee

2022-06-21

Active, closed

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT05316701Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia

DrugOrca-T

Orca Biosystems, Inc.

Phase 3

187

California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, New York

2022-06-21

Active, closed

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

NCT05422222Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

210

California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Minnesota, Missouri

2022-06-21

Active, closed

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

NCT05270837Phenylketonuria (PKU)

DrugPegvaliase

BioMarin Pharmaceutical

Phase 3

Arizona, Arkansas, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts

2022-06-17

Active, closed

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma

DrugsLoncastuximab Tesirine·Mosunetuzumab·Polatuzumab Vedotin·Glofitamab

ADC Therapeutics S.A.

Phase 1

154

California, Florida, Georgia, Iowa, Massachusetts, Minnesota, New York, Ohio

2022-06-17

Recruiting

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

NCT05438732Age-Related Macular Degeneration, Geographic Atrophy

VisionCare, Inc.

Not applicable

125

California, Florida, Massachusetts, Michigan, Nebraska, New Jersey, North Carolina, Ohio

2022-06-16

Active, closed

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156Endogenous Cushing's Syndrome

DrugOsilodrostat

RECORDATI GROUP

Observational

206

Arizona, Georgia, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Minnesota

2022-06-13

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Arizona, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts, Michigan

2022-06-10

Active, closed

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766Gastrointestinal Tract Malignancies

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Fluorouracil

Arcus Biosciences, Inc.

Phase 2

332

Arizona, California, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio

2022-06-10

Recruiting

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor

DrugNavlimetostat

Bristol-Myers Squibb

Phase 1

336

Arizona, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, New Jersey

2022-06-09

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts

2022-06-09

Active, closed

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710Transplant Rejection

DrugsAntithymocyte globulin·Riliprubart·Immunoglobulin·IVIG

Sanofi

Phase 2

California, Massachusetts, New York, Wisconsin

2022-06-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

NCT05144256Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

Arizona, California, Georgia, Massachusetts, Nevada, New York, Pennsylvania, Texas

2022-06-08

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

California, Colorado, Connecticut, District of Columbia, Florida, Kansas, Massachusetts, Michigan

2022-06-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

California, Colorado, Georgia, Illinois, Massachusetts, Michigan, North Carolina, Pennsylvania

2022-06-06

Recruiting

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

NCT05813678Phenylketonuria (PKU)

DrugPegvaliase

BioMarin Pharmaceutical

Observational

450

Colorado, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Oregon, Pennsylvania

2022-06-06

Active, closed

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

NCT05115110Spinal Muscular Atrophy (SMA)

DrugsRO7204239·Risdiplam

Hoffmann-La Roche

Phase 2/3

Massachusetts, New York

2022-06-02

Active, closed

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727Glycogen Storage Disease

ModernaTX, Inc.

Phase 1/2

Connecticut, Massachusetts, North Carolina, Ohio, Pennsylvania, Texas, Utah

2022-06-01

Active, closed

STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures

NCT04835428Vertebral Compression Fracture, Compression Fracture, Vertebral Compression

AgNovos Healthcare, LLC

Not applicable

408

Alabama, Arizona, Florida, Illinois, Kansas, Louisiana, Massachusetts, New York

2022-05-31

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT05379985Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

DrugCetuximab

Revolution Medicines, Inc.

Phase 1/2

754

California, Florida, Georgia, Louisiana, Maryland, Massachusetts, New York, Ohio

2022-05-31

Active, closed

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

NCT05174767Acute Aortic Dissection

Artivion Inc.

Not applicable

115

Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts

2022-05-27

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

NCT05434234Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

312

California, Colorado, District of Columbia, Massachusetts, Michigan, Missouri, New Mexico, New York

2022-05-25

Active, closed

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

NCT06157567Skin Laxity, Wrinkle, Skin Condition

Candela Corporation

Not applicable

500

Florida, Massachusetts, North Carolina, Virginia

2022-05-24

Active, closed

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703Relapsing-remitting Multiple Sclerosis

DrugsFingolimod·Ocrelizumab

Hoffmann-La Roche

Phase 3

188

California, Colorado, District of Columbia, Maryland, Massachusetts, Missouri, Ohio, Pennsylvania

2022-05-19

Active, closed

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

NCT05368259Obesity

Allurion Technologies

Not applicable

1,000

Arizona, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Missouri

2022-05-12

Active, closed

ALTERRA Post-Approval Study

NCT05378386Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation

Edwards Lifesciences

Observational

150

Alabama, Arkansas, California, Colorado, Florida, Illinois, Massachusetts, Missouri

2022-05-12

Active, closed

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705Breast Cancer

DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 1

260

Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Missouri, New York

2022-05-11

Active, closed

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

NCT05069558Stroke, Patent Foramen Ovale, PFO

Occlutech International AB

Not applicable

450

Arizona, California, Colorado, District of Columbia, Illinois, Kentucky, Maine, Massachusetts

2022-05-09

Active, closed

Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

NCT05811754Herpes Zoster

GlaxoSmithKline

Observational

2,844

Massachusetts

2022-05-09

Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT04771572Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia

Newave Pharmaceutical Inc

Phase 1

100

Illinois, Massachusetts, North Carolina, Ohio, Texas, Utah

2022-05-08

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Arizona, California, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Michigan

2022-05-03

Active, closed

STOP AF First Post-Approval Study

NCT05227053Paroxysmal Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

200

Alaska, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan, Ohio

2022-04-28

Recruiting

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

NCT04991831Tremor Associated With Tremor Dominant Parkinson's Disease

InSightec

Observational

Florida, Illinois, Massachusetts, New York, North Carolina, Ohio

2022-04-28

Active, closed

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT05232838Hydrocephalus, Normal Pressure, Hydrocephalus

CereVasc Inc

Not applicable

Connecticut, Florida, Kansas, Kentucky, Massachusetts, New York, Rhode Island, Virginia

2022-04-20

Active, closed

Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study

NCT05291884Heart Failure, Acute Decompensated Heart Failure

Abiomed Inc.

Not applicable

Georgia, Illinois, Massachusetts, New Jersey, Ohio

2022-04-20

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts

2022-04-14

Active, closed

CONVERGE Post-Approval Study (PAS)

NCT05393180Chronic Atrial Fibrillation

AtriCure, Inc.

Not applicable

California, Connecticut, Florida, Georgia, Kentucky, Maryland, Massachusetts, New Jersey

2022-04-13

Active, closed

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810Non Small Cell Lung Cancer, KRAS Activating Mutation

DrugsAvutometinib and sotorasib and defactinib·Sotorasib

Verastem, Inc.

Phase 1/2

153

Colorado, District of Columbia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri

2022-04-12

Active, closed

Multi-Center Study of ManNAc for GNE Myopathy

NCT04231266GNE Myopathy

Leadiant Biosciences, Inc.

Phase 2

California, Iowa, Kansas, Maryland, Massachusetts, Missouri, New York, Ohio

2022-04-05

By invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2/3

600

Alabama, California, Colorado, Florida, Georgia, Massachusetts, Michigan, New York

2022-04-05

By invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

NCT05296447Diabetic Retinopathy, DR

DrugsEylea·Aflibercept

AbbVie

Phase 2

100

Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Jersey

2022-04-04

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Arizona, California, Colorado, Connecticut, District of Columbia, Maryland, Massachusetts, Michigan

2022-03-29

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436Chronic Lymphocytic Leukemia (CLL)

DrugsVenclexta·Obinutuzumab·Venetoclax

AbbVie

Phase 2

California, Georgia, Iowa, Massachusetts, Michigan, Minnesota, Mississippi, New Jersey

2022-03-28

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Alabama, California, Florida, Indiana, Massachusetts, Michigan, Mississippi, Pennsylvania

2022-03-24

Active, closed

Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation

NCT05269862Parkinson Disease

Abbott Medical Devices

Not applicable

100

Arizona, California, Florida, Illinois, Indiana, Massachusetts, New Hampshire, Ohio

2022-03-24

By invitation

Global Utilization And Registry Database for Improved preservAtion of doNor Livers

NCT05082077Liver Diseases, Liver Dysfunction, Liver Transplant Disorder, Liver Transplant Rejection

Paragonix Technologies

Observational

2,000

Alabama, California, Florida, Georgia, Maryland, Massachusetts, Nebraska, North Carolina

2022-03-15

Recruiting

Physio-Anatomy Clinical Data Collection Study

NCT05312164Coronary Stenosis

Gentuity, LLC

Observational

150

California, Florida, Georgia, Massachusetts, Minnesota, Ohio

2022-03-14

Active, closed

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400Breast Cancer, Solid Tumors

DrugsPF-07104091·Atirmociclib

Pfizer

Phase 1/2

235

California, Massachusetts, Michigan, Missouri, Texas, Washington

2022-03-14

Recruiting

Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes

NCT04496479End Stage Liver Disease

LyGenesis, Inc.

Phase 2

Massachusetts, Texas

2022-03-11

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700Solid Tumors

ORIC Pharmaceuticals

Phase 1/2

350

California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York

2022-03-10

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781Multiple Myeloma

DrugCilta-cel

Janssen Research & Development, LLC

Phase 4

295

Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Massachusetts

2022-03-09

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

Arkansas, Florida, Illinois, Maryland, Massachusetts, Michigan, Missouri, New Jersey

2022-03-09

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Alabama, California, Colorado, District of Columbia, Georgia, Massachusetts, Michigan, North Carolina

2022-03-08

Active, closed

INTIBIA Pivotal Study

NCT05250908Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases

Coloplast A/S

Not applicable

208

California, District of Columbia, Florida, Georgia, Idaho, Kansas, Massachusetts, Michigan

2022-03-07

Recruiting

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

NCT05304962Breast Cancer

DrugRGT-419B

Regor Pharmaceuticals Inc.

Phase 1

California, Florida, Georgia, Massachusetts, Missouri, New York

2022-03-04

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Arizona, California, Colorado, Maryland, Massachusetts, New Hampshire, New Jersey, New York

2022-03-04

Recruiting

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706Short Bowel Syndrome

Hanmi Pharmaceutical Company Limited

Phase 2

Massachusetts, Ohio

2022-03-03

Active, closed

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

NCT05090371Relapsing-Remitting Multiple Sclerosis

DrugOfatumumab

Novartis Pharmaceuticals

Phase 4

136

Alabama, Arizona, California, Florida, Idaho, Louisiana, Maryland, Massachusetts

2022-03-02

Active, closed

Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends

NCT04865679Symptomatic Neuroma, Amputation, Chronic Nerve Pain

Axogen Corporation

Not applicable

Massachusetts, Texas

2022-03-02

Active, closed

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973Amyloidosis

DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

151

California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina

2022-03-01

Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax

Sumitomo Pharma America, Inc.

Phase 1/2

606

California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, New Jersey

2022-02-28

Active, closed

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

NCT05279755Amyotrophic Lateral Sclerosis

ProJenX

Phase 1

Massachusetts, Texas

2022-02-26

Active, closed

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

NCT05222802Glioblastoma Multiforme

Katmai Pharmaceuticals Inc.

Phase 1

California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee, Utah

2022-02-25

Active, closed

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

NCT05230537Age-Related Macular Degeneration

DrugIptacopan

Novartis Pharmaceuticals

Phase 2

168

California, Colorado, Florida, Indiana, Louisiana, Maryland, Massachusetts, New Jersey

2022-02-17

Active, closed

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

NCT05239143Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer

DrugRimiducid

Poseida Therapeutics, Inc.

Phase 1

180

California, Colorado, Iowa, Kansas, Maryland, Massachusetts, Nebraska, New York

2022-02-15

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320Crohn's Disease (CD)

DrugVedolizumab

Takeda

Phase 3

120

Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts

2022-02-10

Active, closed

LIFE-BTK PK Sub-study

NCT05208905Critical Limb Ischemia (CLI)

Abbott Medical Devices

Not applicable

Florida, Massachusetts, Oklahoma

2022-02-10

Active, closed

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

DrugRozanolixizumab

UCB Biopharma SRL

Phase 3

113

Arizona, California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts

2022-02-02

Active, closed

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

NCT04980833PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

Massachusetts

2022-01-27

Recruiting

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC

DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin

Synthekine

Phase 1/2

364

Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts

2022-01-25

Recruiting

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

NCT05184335Schizophrenia

Reviva Pharmaceuticals

Phase 3

690

Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts

2022-01-24

Active, closed

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

NCT05067790Spinal Muscular Atrophy

DrugNusinersen

Biogen

Phase 3

Arizona, California, Georgia, Massachusetts, Michigan, New York, North Carolina, Pennsylvania

2022-01-21

Active, closed

ADH1 and ADH2 Disease Monitoring Study (DMS)

NCT05227287Autosomal Dominant Hypocalcemia

Calcilytix Therapeutics, Inc., a BridgeBio company

Observational

California, Colorado, Florida, Indiana, Massachusetts, Minnesota, North Carolina, Ohio

2022-01-20

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma

DrugsZilovertamab vedotin·Granulocyte Colony-Stimulating Factor·Riabni·G-Csf

Merck Sharp & Dohme LLC

Phase 2/3

290

Arizona, California, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan

2022-01-14

Active, closed

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628Trigeminal Neuralgia

Noema Pharma AG

Phase 2/3

166

California, Florida, Georgia, Massachusetts, Nevada, New York, Ohio

2022-01-11

Active, closed

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer

DrugsTrastuzumab emtansine·Trastuzumab·Pembrolizumab

Ascendis Pharma Oncology Division A/S

Phase 1/2

320

California, Illinois, Kentucky, Massachusetts, New Jersey, New York, North Carolina, Ohio

2022-01-11

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Missouri

2022-01-04

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT05071300Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

151

Arizona, Indiana, Maryland, Massachusetts, New York, North Carolina, Oregon, Washington

2022-01-04

Active, closed

A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

NCT04961840Constipation, Pregnancy

Takeda

Observational

100

Massachusetts

2022-01-01

Active, closed

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 2

210

Arizona, Arkansas, California, Connecticut, Florida, Indiana, Massachusetts, Michigan

2021-12-28

Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

NCT04925479Myeloid Leukemia, Philadelphia Positive

DrugABL001

Novartis Pharmaceuticals

Phase 1/2

Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah

2021-12-27

Active, closed

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

NCT05127226Angelman Syndrome

DrugObudanersen

Ionis Pharmaceuticals, Inc.

Phase 1/2

California, Colorado, Illinois, Massachusetts, North Carolina, Texas

2021-12-22

Active, closed

A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

NCT05197036Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis

Smith & Nephew, Inc.

Observational

299

Georgia, Massachusetts, Michigan, New York, North Carolina, Oregon, South Carolina, Tennessee

2021-12-21

Active, closed

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226Neuroendocrine Tumors

DrugsFOLFOX (Folinic acid·Everolimus·Fluorouracil·Oxaliplatin

ITM Solucin GmbH

Phase 3

259

California, Colorado, Florida, Massachusetts, Minnesota, Missouri, New York, North Carolina

2021-12-21

Active, closed

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

NCT05145062Blood and Lymphatic Diseases

Sangamo Therapeutics

Observational

California, Georgia, Massachusetts, Michigan, Minnesota

2021-12-21

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

194

California, Massachusetts, New York, North Carolina, Pennsylvania

2021-12-20

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Tennessee, Texas

2021-12-20

By invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

NCT05210803Neovascular Age-Related Macular Degeneration (nAMD)

DrugsLucentis·Ranibizumab

AbbVie

Phase 2

116

Arizona, California, Georgia, Maryland, Massachusetts, Minnesota, Nevada, New Mexico

2021-12-20

Active, closed

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Phase 3

Alabama, California, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri

2021-12-17

Recruiting

ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

NCT05004051Abdominal Aortic Aneurysms

ViTAA Medical Solutions

Observational

200

Alabama, Massachusetts, North Carolina, Washington

2021-12-15

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

360

California, Colorado, Massachusetts, Michigan

2021-12-14

Active, closed

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals

Observational

207

Arizona, District of Columbia, Massachusetts, Minnesota, Ohio, Pennsylvania, Texas

2021-12-13

Active, closed

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969Locally Advanced or Metastatic Solid Tumours

DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 2

126

California, Georgia, Idaho, Massachusetts, Michigan, New York, Oregon, Texas

2021-12-10

Active, closed

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

NCT05079282Relapsed or Refractory T Cell Lymphoma

DrugONO-4685

Ono Pharmaceutical Co., Ltd.

Phase 1

217

Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Missouri, New Jersey

2021-12-10

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Alabama, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts, New Mexico

2021-12-10

Recruiting

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

NCT05197270Neovascular (Wet) Age-Related Macular Degeneration

DrugsAflibercept IVT·4D-150 IVT

4D Molecular Therapeutics

Phase 1/2

215

Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Massachusetts

2021-12-09

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts

2021-12-08

Active, closed

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugRilzabrutinib

Sanofi

Phase 2

California, District of Columbia, Florida, Massachusetts

2021-12-07

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Alabama, Arkansas, Delaware, Florida, Georgia, Iowa, Massachusetts, Michigan

2021-12-01

Active, closed

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

NCT04910022Glioblastoma, Diffuse Glioma

DrugsNMS-03305293·Temozolomide

Nerviano Medical Sciences

Phase 1/2

150

Arizona, California, Florida, Massachusetts, Minnesota, New York, Texas, Utah

2021-12-01

Active, closed

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

NCT04632953Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Ultragenyx Pharmaceutical Inc

Observational

150

Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Minnesota

2021-11-30

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3

534

Alabama, California, Colorado, Georgia, Massachusetts, Michigan, Minnesota, New York

2021-11-30

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT04770779Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

258

Arizona, California, Massachusetts, Michigan, New York, North Carolina, Pennsylvania, Washington

2021-11-30

Active, closed

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Small-Cell Lung Cancer

DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab

Hoffmann-La Roche

Phase 3

660

Georgia, Illinois, Maine, Massachusetts, Michigan, New York, Ohio, Rhode Island

2021-11-18

Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)

DrugCLN-049

Cullinan Therapeutics Inc.

Phase 1

Alabama, California, Florida, Georgia, Massachusetts, New York, North Carolina, Ohio

2021-11-18

Active, closed

A Study of Lu AF82422 in Participants With Multiple System Atrophy

NCT05104476Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 2

California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Nebraska, New York

2021-11-16

Active, closed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052Differentiated Thyroid Cancer (DTC)

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Phase 3

153

Illinois, Massachusetts

2021-11-15

Active, closed

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

NCT04851717Pediatric ALL

DrugRemimazolam

Acacia Pharma Ltd

Phase 2/3

100

California, Massachusetts, Minnesota, Pennsylvania, Texas

2021-11-15

Recruiting

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

140

Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, New York

2021-11-09

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts

2021-11-07

Active, closed

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

NCT04980872PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

Merck Sharp & Dohme LLC

Phase 2

Georgia, Massachusetts, Ohio, Texas, Washington

2021-11-02

Active, closed

Desara ® One Single Incision Sling 522 Study

NCT04772131Stress Urinary Incontinence

Caldera Medical, Inc.

Not applicable

300

Arizona, Florida, Idaho, Indiana, Kentucky, Massachusetts, Missouri, Nevada

2021-11-01

Active, closed

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05117476Advanced Solid Tumor, NSCLC

DrugsCLN-619·Carboplatin (AUC 6)·Dato-DXd·Pemetrexed

Cullinan Therapeutics Inc.

Phase 1

440

Alabama, California, Florida, Massachusetts, Michigan, New Jersey, New York, North Carolina

2021-10-29

Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT04981119Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer

A2 Biotherapeutics Inc.

Observational

500

Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio

2021-10-29

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Massachusetts, New York

2021-10-28

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Alaska, California, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania

2021-10-28

Active, closed

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

389

California, Colorado, Illinois, Maryland, Massachusetts, Minnesota, Missouri, New York

2021-10-27

Active, closed

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

NCT04829604HER2 Positive Metastatic Breast Cancer

DrugARX788

Ambrx, Inc.

Phase 2

California, Georgia, Illinois, Kentucky, Maryland, Massachusetts, Missouri, Nebraska

2021-10-26

Active, closed

Harmony TPV Post-Approval Study

NCT05077774Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation

Medtronic Cardiovascular

Not applicable

174

Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Missouri

2021-10-25

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Arizona, California, Georgia, Maryland, Massachusetts, Michigan, New York, Tennessee

2021-10-25

Active, closed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor

DrugsCAM2029·Octreotide LAR

Camurus AB

Phase 3

332

Arizona, California, Colorado, Florida, Kentucky, Louisiana, Massachusetts, Minnesota

2021-10-22

Active, closed

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

NCT04857372Mesothelioma

Novartis Pharmaceuticals

Phase 1

137

California, Illinois, Massachusetts, Ohio, Texas

2021-10-21

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

California, Louisiana, Maryland, Massachusetts, Missouri, New Mexico, New York, North Carolina

2021-10-18

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

California, Florida, Georgia, Massachusetts, Michigan, New York, Ohio, Oregon

2021-10-18

By invitation

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

NCT04930289Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis

Paragonix Technologies

Observational

3,500

Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Pennsylvania

2021-10-15

Recruiting

US National OCS Liver Perfusion (OLP) Registry

NCT05940857Liver Transplant

TransMedics

Observational

100,000

Alabama, Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Michigan

2021-10-14

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Ohio, Pennsylvania

2021-10-14

Active, closed

OCS Liver Perfusion (OLP) Post-Approval Registry

NCT05074160Liver Transplant

TransMedics

Observational

166

Alabama, California, Georgia, Massachusetts, Michigan, Nebraska, North Carolina, Texas

2021-10-14

Active, closed

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 3

123

California, Colorado, Kansas, Massachusetts, Minnesota, New York, North Carolina, Ohio

2021-10-14

Recruiting

STRIVE Post-Market Registry Study

NCT04302272Emphysema

Olympus Corporation of the Americas

Observational

150

Arizona, California, Florida, Illinois, Louisiana, Maryland, Massachusetts, Mississippi

2021-10-09

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Colorado, Florida, Kentucky, Massachusetts, North Carolina, Oregon, South Dakota, Tennessee

2021-10-06

Active, closed

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma

DrugCOVID-19 Vaccine

GeoVax, Inc.

Phase 2

California, Maryland, Massachusetts, New York, North Carolina, Washington

2021-09-27

Active, closed

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

NCT04884815Wilson Disease

Ultragenyx Pharmaceutical Inc

Phase 1/2

California, Illinois, Indiana, Massachusetts, Michigan, North Carolina, Ohio, Tennessee

2021-09-27

Recruiting

Innovations in Genicular Outcomes Registry

NCT05495334Knee Osteoarthritis

Pacira Pharmaceuticals, Inc

Observational

10,000

Arizona, California, Florida, Louisiana, Maryland, Massachusetts, Nebraska, New Jersey

2021-09-23

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Arizona, California, Colorado, Delaware, Idaho, Illinois, Maryland, Massachusetts

2021-09-20

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Arizona, California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts

2021-09-20

Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605Relapsed/Refractory Multiple Myeloma

DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab

BeOne Medicines

Phase 1/2

246

Alabama, California, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey

2021-09-16

Active, closed

OCS Heart Perfusion Post-Approval Registry

NCT05047068Transplant

TransMedics

Observational

350

California, Connecticut, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan

2021-09-13

Active, closed

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059Non-small Cell Lung Cancer

DrugCarboplatin

AstraZeneca

Phase 3

Maryland, Massachusetts

2021-09-12

Recruiting

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT04704323Lymphocytic Leukemia, Chronic, SLL

Catapult Therapeutics

Phase 1

Massachusetts, North Carolina

2021-09-10

Recruiting

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

NCT04998396Canavan Disease

Aspa Therapeutics

Phase 1/2

California, Illinois, Massachusetts, New York

2021-09-08

Active, closed

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

NCT05023551High Grade Glioma, Glioblastoma Multiforme

Sumitomo Pharma America, Inc.

Early Phase 1

California, Massachusetts, Missouri, New Jersey, New York, Utah

2021-09-08

Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT04890613Advanced Solid Tumor

Senhwa Biosciences, Inc.

Phase 1

California, Florida, Massachusetts, New York, Ohio, Pennsylvania

2021-09-08

Active, closed

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

NCT05035030Alagille Syndrome

DrugOdevixibat

Albireo, an Ipsen Company

Phase 3

California, Georgia, Indiana, Maryland, Massachusetts, Missouri, New York, North Carolina

2021-09-03

Active, closed

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT05067140Prostate Cancer Metastatic

DrugsLuxdegalutamide·Abiraterone·Prednisolone·Prednisone

Novartis Pharmaceuticals

Phase 1/2

164

California, Connecticut, Florida, Maryland, Massachusetts, Michigan, New York, Pennsylvania

2021-09-02

Active, closed

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282Desmoid, Desmoid Tumor

Immunome, Inc.

Phase 2/3

198

Arizona, California, Florida, Illinois, Massachusetts, Michigan, Missouri, New York

2021-09-01

Active, closed

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

NCT04956744Multiple Sclerosis

ImStem Biotechnology

Phase 1

Georgia, Massachusetts, Utah

2021-08-31

Active, closed

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967Early Detection of Cancer, Cancer

GRAIL, Inc.

Observational

14,633

Arizona, California, Florida, Louisiana, Massachusetts, Oregon, Pennsylvania, South Carolina

2021-08-23

Active, closed

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

NCT04994795Non-small Cell Lung Cancer Metastatic

Sophia Genetics SAS

Observational

4,000

Iowa, Massachusetts, Minnesota, New York, Utah, Wisconsin

2021-08-21

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Michigan

2021-08-19

Active, closed

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

NCT05007782Advanced Solid Tumor

DrugsDenikitug·Zimberelimab

Gilead Sciences

Phase 1

304

California, Connecticut, Massachusetts, Tennessee, Texas, Wisconsin

2021-08-18

Active, closed

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

NCT04624230Ulcerative Colitis

DrugTofacitinib

Pfizer

Phase 3

118

California, Connecticut, Florida, Georgia, Massachusetts, New York, Ohio, Pennsylvania

2021-08-12

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

California, Illinois, Iowa, Maryland, Massachusetts, Michigan, Missouri, New York

2021-08-12

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis

DrugSparsentan

Travere Therapeutics, Inc.

Phase 2

California, Delaware, Florida, Iowa, Massachusetts, Michigan, Minnesota, Missouri

2021-08-12

Active, closed

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975EPP, XLP

Tanabe Pharma America, Inc.

Phase 3

286

California, Florida, Massachusetts, Michigan, Missouri, New York, North Carolina, Ohio

2021-08-10

Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma

DrugsObinutuzumab·Keytruda·Pembrolizumab

Simcha IL-18, Inc.

Phase 1/2

316

Arizona, Colorado, Connecticut, Florida, Massachusetts, New York

2021-08-06

Active, closed

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

NCT04852783Aneurysm, Intracranial

Cerus Endovascular, Inc.

Phase 4

250

Colorado, Florida, Illinois, Kansas, Massachusetts, New York, North Carolina, Pennsylvania

2021-08-06

Active, closed

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

NCT04790370Pulmonary Embolism

DrugsLMWH·Heparin

Boston Scientific Corporation

Phase 4

544

Alabama, California, Delaware, Georgia, Indiana, Kentucky, Maryland, Massachusetts

2021-08-02

Active, closed

MIRACLE of LIFE Study

NCT06074601Preterm Labor, Preterm Birth, Preterm Birth Complication, Preterm Premature Rupture of Membrane

Mirvie

Observational

10,000

California, Florida, Louisiana, Massachusetts, Missouri, Ohio, Pennsylvania, Texas

2021-08-01

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184Multiple Myeloma

DrugsBelantamab mafodotin·Isatuximab

GlaxoSmithKline

Phase 1/2

Georgia, Massachusetts, Michigan, Wisconsin

2021-07-29

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618C3G

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Colorado, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts, New Jersey

2021-07-28

Active, closed

M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study

NCT04982835Cervical Disc Degenerative Disorder

Orthofix Inc.

Not applicable

156

Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Massachusetts

2021-07-26

Recruiting

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288Renal Allograft Recipients

DrugsCyclosporine A·Belatacept·Mycophenolate Mofetil·Tacrolimus

Bristol-Myers Squibb

Phase 3

102

Alabama, California, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts

2021-07-21

Active, closed

Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft.

NCT04615260Degenerative Disc Disease, Spondylolisthesis

Artoss Inc.

Not applicable

Massachusetts

2021-07-19

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Alabama, California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Hampshire

2021-07-19

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

562

Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Missouri

2021-07-16

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts

2021-07-15

Active, closed

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

NCT04554914Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)

DrugTabelecleucel

Pierre Fabre Medicament

Phase 2

190

California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota

2021-07-14

Active, closed

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05044819Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex

DrugCannabidiol

Jazz Pharmaceuticals

Phase 4

154

Arkansas, California, Florida, Georgia, Kansas, Kentucky, Maryland, Massachusetts

2021-07-07

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171Follicular Lymphoma, Marginal Zone Lymphoma

DrugsLenalidomide·Rituximab

Enterome

Phase 1/2

Massachusetts, Minnesota, New York, Washington

2021-07-05

Active, closed

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

NCT04942210Yellow Fever, Healthy Volunteers

DrugYellow fever vaccine

Sanofi Pasteur, a Sanofi Company

Phase 2

568

Georgia, Louisiana, Maryland, Massachusetts, Missouri, Nebraska, New York, Rhode Island

2021-07-01

Recruiting

BostonGene-Integrated Genomic Registry (BIGR)

NCT04991922Malignancy

BostonGene

Observational

100,000

Massachusetts

2021-07-01

Active, closed

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

NCT04635384Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome

CareDx

Observational

307

California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio, Oregon

2021-06-30

Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer

DrugGivastomig

I-Mab Biopharma US Limited

Phase 1

330

California, Colorado, Indiana, Massachusetts, New Jersey, New York, North Carolina, Tennessee

2021-06-29

Active, closed

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

NCT04725994Gastric Cancer

DrugsXelox·Irinotecan

Idience Co., Ltd.

Phase 1/2

California, Louisiana, Massachusetts, New Jersey

2021-06-28

Active, closed

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

NCT04925024Hypoplastic Left Heart Syndrome

Longeveron Inc.

Phase 2

California, Colorado, Georgia, Illinois, Massachusetts, Nebraska, Ohio, Pennsylvania

2021-06-25

Active, closed

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451Congenital Adrenal Hyperplasia

DrugCrinecerfont

Neurocrine Biosciences

Phase 3

103

Alabama, California, Colorado, Connecticut, District of Columbia, Georgia, Indiana, Massachusetts

2021-06-25

Active, closed

Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea

NCT04801771Down Syndrome, Obstructive Sleep Apnea

Inspire Medical Systems, Inc.

Not applicable

Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Virginia, Wisconsin

2021-06-24

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Massachusetts, North Carolina

2021-06-22

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

DrugsSamuraciclib·Ipatasertib·Giredestrant·Phesgo

Hoffmann-La Roche

Phase 1/2

316

California, Massachusetts, New Jersey, North Carolina, Pennsylvania, Tennessee

2021-06-22

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Colorado, Florida, Louisiana, Massachusetts, Missouri, Nebraska, New York, North Carolina

2021-06-15

Active, closed

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

NCT04768972Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc.

Phase 3

California, Maryland, Massachusetts, Missouri, New York, Ohio, Utah

2021-06-14

Active, closed

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

NCT04891757Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes

DrugsDecitabine·Cytarabine

Foghorn Therapeutics Inc.

Phase 1

144

California, Massachusetts, New York, Tennessee, Texas

2021-06-14

Active, closed

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

NCT04676477Non-Small Cell Lung Cancer (NSCLC)

DrugsPatritumab deruxtecan·Osimertinib

Daiichi Sankyo

Phase 1

246

California, Connecticut, District of Columbia, Illinois, Massachusetts, Michigan, New Hampshire, New York

2021-06-11

Active, closed

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma

DrugValemetostat Tosylate

Daiichi Sankyo

Phase 2

155

California, Colorado, Georgia, Illinois, Massachusetts, Minnesota, Missouri, New Jersey

2021-06-03

Active, closed

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

NCT04849741Alexander Disease

Ionis Pharmaceuticals, Inc.

Phase 3

California, Georgia, Massachusetts, Pennsylvania

2021-06-01

Active, closed

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

NCT04736121Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma

Sirtex Medical

Not applicable

100

California, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina, Ohio

2021-05-28

Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

150

California, Connecticut, Georgia, Massachusetts, Missouri, New York, Pennsylvania, Texas

2021-05-26

Active, closed

Molecular Assessment and Profiling of Liver Transplant Recipients

NCT04793360Liver Transplantation, Biomarkers

CareDx

Observational

1,500

California, District of Columbia, Florida, Georgia, Kansas, Louisiana, Maryland, Massachusetts

2021-05-26

Active, closed

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

NCT06596252Eosinophilic Esophagitis

DrugBudesonide

Dr. Falk Pharma GmbH

Phase 3

308

Arizona, Arkansas, California, Florida, Idaho, Massachusetts, Michigan, Minnesota

2021-05-21

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

California, Illinois, Indiana, Kentucky, Massachusetts, Michigan, New Mexico, New York

2021-05-19

Active, closed

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

DrugTofersen

Biogen

Phase 3

158

Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri

2021-05-17

Active, closed

A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants

NCT04903288AADC Deficiency

PTC Therapeutics

Phase 2

Massachusetts, North Carolina, Ohio, Texas

2021-05-12

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts?page=3

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,830 of those studies with a site in Massachusetts.

How many clinical trials are recruiting in Massachusetts?

953 of the 1,830 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 43 have not yet opened recruitment, 776 are active but closed to new participants, and 58 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.